Clinical trial
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
NCT02633293
Study timeline
Study start (actual)2016-09-15Date precision: day
Registry last updated2022-12-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Pulmonary Hypertensionunresolved
Interstitial Lung Diseaseunresolved
Interventions
Sponsors & collaborators
United Therapeuticslead sponsor
Mapped research locations
ChicagoIllinois, United States4New YorkNew York, United States3HoustonTexas, United States3BostonMassachusetts, United States3IndianapolisIndiana, United States3JacksonvilleFlorida, United States3Los AngelesCalifornia, United States2DallasTexas, United States2BaltimoreMaryland, United States2ClevelandOhio, United States2PittsburghPennsylvania, United States2CincinnatiOhio, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02633293 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.